A Multicenter Study to Collect Samples for Future Evaluation of Biomarkers and Genetic Mutations in Patients Exposed to Adalimumab With Crohn's Disease (CD) or Ulcerative Colitis (UC) Who Developed Hepatosplenic T-Cell Lymphoma (HSTCL)
Phase of Trial: Phase IV
Latest Information Update: 21 Dec 2018
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacodynamics
- Sponsors AbbVie
- 11 Jun 2018 Planned End Date changed from 30 Sep 2019 to 13 Mar 2022.
- 11 Jun 2018 Planned primary completion date changed from 30 Sep 2019 to 13 Mar 2022.
- 23 Mar 2014 New trial record